Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals announced that its board has authorized a share buyback program on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its earnings results on Wednesday, August, 9th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.05. The firm earned $65.20 million during the quarter, compared to the consensus estimate of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The company's revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.23 EPS. View Amphastar Pharmaceuticals' Earnings History.

6 brokers have issued 1-year price targets for Amphastar Pharmaceuticals' shares. Their predictions range from $16.00 to $29.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $19.83 in the next year. View Analyst Ratings for Amphastar Pharmaceuticals.

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (5/16/2017)
• 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
• 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
• 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Some companies that are related to Amphastar Pharmaceuticals include Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Aceto Corporation (ACET), Tetraphase Pharmaceuticals (TTPH), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), BioDelivery Sciences International (BDSI), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), Diurnal Group PLC (DNL) and BioLife Solutions (BLFS).

Amphastar Pharmaceuticals' management team includes the folowing people:

• Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board
• Jason B. Shandell J.D., President, General Counsel, Director
• Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
• William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc.
• Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc
• Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.
• Michael A. Zasloff M.D. Ph.D., Lead Independent Director
• Richard Koo CPA, Independent Director
• Howard S. Lee Ph.D., Independent Director
• Floyd F. Petersen, Independent Director

Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.80%), Vanguard Group Inc. (5.28%), Dimensional Fund Advisors LP (2.91%), Federated Investors Inc. PA (2.29%), State Street Corp (2.10%) and Teachers Advisors LLC (1.20%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., Citadel Advisors LLC, Acadian Asset Management LLC, Cornerstone Capital Management Holdings LLC., BlackRock Inc., JPMorgan Chase & Co., State Street Corp and Russell Investments Group Ltd.. Company insiders that have sold Amphastar Pharmaceuticals stock in the last year include Diane G Gerst, Floyd F Petersen, Howard Lee, Jason B Shandell, Michael A Zasloff, Richard K Prins and Rong Zhou. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Vanguard Group Inc., UBS Asset Management Americas Inc., Citigroup Inc., Bank of Montreal Can, Argent Capital Management LLC, Fisher Asset Management LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $16.10.